Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 401

Results For "new"

5305 News Found

FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Drug Approval | June 01, 2022

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date


Tetra Bio-Pharma appoints CFO
People | June 01, 2022

Tetra Bio-Pharma appoints CFO

Auld is a seasoned Financial Executive with over 30 years of relevant experience


North India’s first biotech park at Kathua, J&K inaugurated
News | May 30, 2022

North India’s first biotech park at Kathua, J&K inaugurated

Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas


Strides receives USFDA approval for Ibuprofen Oral Suspension
Drug Approval | May 30, 2022

Strides receives USFDA approval for Ibuprofen Oral Suspension

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)


MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData
Biotech | May 29, 2022

MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData

RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised


JBCL rebrands as JB
News | May 29, 2022

JBCL rebrands as JB

JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India


Venus Remedies registers 9.22 % growth in annual sales for FY22
News | May 29, 2022

Venus Remedies registers 9.22 % growth in annual sales for FY22

The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal


USFDA approves two Opdivo-based regimens
Biotech | May 29, 2022

USFDA approves two Opdivo-based regimens

Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers


USFDA approves Novartis Kymriah CAR-T cell therapy
Biotech | May 29, 2022

USFDA approves Novartis Kymriah CAR-T cell therapy

68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile